<code id='A966F4FA4E'></code><style id='A966F4FA4E'></style>
    • <acronym id='A966F4FA4E'></acronym>
      <center id='A966F4FA4E'><center id='A966F4FA4E'><tfoot id='A966F4FA4E'></tfoot></center><abbr id='A966F4FA4E'><dir id='A966F4FA4E'><tfoot id='A966F4FA4E'></tfoot><noframes id='A966F4FA4E'>

    • <optgroup id='A966F4FA4E'><strike id='A966F4FA4E'><sup id='A966F4FA4E'></sup></strike><code id='A966F4FA4E'></code></optgroup>
        1. <b id='A966F4FA4E'><label id='A966F4FA4E'><select id='A966F4FA4E'><dt id='A966F4FA4E'><span id='A966F4FA4E'></span></dt></select></label></b><u id='A966F4FA4E'></u>
          <i id='A966F4FA4E'><strike id='A966F4FA4E'><tt id='A966F4FA4E'><pre id='A966F4FA4E'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:explore    Page View:9564

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In